If you previously attended and received credit for the live CME/CE-certified conference, 14th Annual School of Breast Oncology®, which was held November 3-5, 2016, in Atlanta, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will Physicians’ Education Resource®, LLC (PER®), award, duplicate credit for the activity.
An increasing number of oncologists are focusing their clinical practices on the treatment of breast cancer, creating a need for specialized education. The School of Breast Oncology®, which has been held annually since 2003, was developed to advance patient care by providing a curriculum-based program focused exclusively on breast cancer clinical management. This intensive 3-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment, with lectures emphasizing clinical implications presented by leading clinical investigators. Not only does the School of Breast Oncology® provide a comprehensive overview for fellows or oncologists who are new to practice, it also serves as a valuable refresher course with updates on the latest data and changes to standards of care for the oncologist who has been in practice for several years or more. This online activity captures all of the lectures presented at the live 2016 School of Breast Oncology®, organizes them in a convenient modular format, and summarizes the existing data for each topic with an emphasis on the evidence-based foundations for optimal, individualized decision making in the clinic.
Instructions for Receiving Credit
In order to receive a CME/CE certificate, participants must complete the pretest, view any number of the 10 slide modules, and complete the posttest (with a passing score of 70% or higher), evaluation, and request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.
This educational program is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with breast cancer.
The following individuals have no relevant financial relationships with commercial interests to disclose:
Douglas W. Arthur, MD; David Euhus, MD, FACS; William J. Gradishar, MD, FASCO, FACP; Karin Hahn, MD, MSc, MPH; Syed A. Hoda, MD; Frankie Ann Holmes, MD, FACP; Anne Moore, MD; Soonmyung Paik, MD; Debra Patt, MD, MPH, MBA; Edward H. Romond, MD; Jeffrey N. Weitzel, MD.
The staff of Physicians’ Education Resource®, LLC.
The following individuals have relevant financial relationships with commercial interests to disclose:
Carey K. Anders, MD – Consultant: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Lilly, Genentech, Nektar Therapeutics, Kadmon Corporation; Research Funding: Novartis, Sanofi, to-BBB Therapeutics, Geron, AngioChem, Merrimack Pharmaceuticals, Puma Biotechnology, Lilly, Kadmon Corporation – all uncompensated; Carol Fabian, MD - Grant/Research Support: No monetary grants other than BCRF and Komen. Institution Receives Duavee from Pfizer for a clinical prevention trial and omega-3 fatty acids and placebo from DSM for a clinical trial; Other: DSM provides study agent (DHA and placebo) for clinical trial; Claudine Isaacs, MD – Grant/Research Support: Tesaro, Pfizer; Consultant: Pfizer, AstraZeneca; Speaker’s Bureau: Genentech, Pfizer; Henry M. Kuerer, MD, PhD, FACS – Grant/Research Support: Genomic Health; Consultant: Gerson Lehrman Group; Other: Editor, NEJM Medical Group and McGraw- Hill Publishing; Charles Loprinzi, MD – Grant/Research Support: Bristol-Myers Squibb, Pfizer, Janssen; Consultant: Cubist Pharmaceuticals, Mitsubishi Tanabe Pharma, Coronado Biosciences Inc, Lpath, Mundipharma, PledPharma; Eleftherios Mamounas, MD, MPH, FACS – Consultant: Genomic Health Inc, Genentech, Pfizer, Novartis, Biotheranostics, Bayer, GRAIL, Cellcuity; Speaker’s Bureau: Genomic Health, Roche/Genentech; Anne McTiernan, MD, PhD – Consultant: Pro-Change Behavior Systems, Inc; Shareholder: Merck (husband); Ruth O’Regan, MD – Grant/Research Support: Eisai, Pfizer, Novartis; Consultant: Pfizer, Lilly, Biotheranostics; Joyce O’Shaughnessy, MD – Advisory Board/Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept, Eisai, Genentech, GSK, Lilly, J&J, Merrimack, Novartis, Pfizer, Roche, Sanofi, Takeda, Medfusion; Lori J. Pierce, MD, FASTRO – Shareholder: PFS Genomics (founder's shares); Other: UpToDate (Royalties); Elizabeth Rafferty, MD – Grant/Research Support: Hologic, Inc, Investigation of tomosynthesis; Hope S. Rugo, MD – Grant/Research Support: GSK, Genentech/Roche, Merck, Novartis, Plexxikon, Eisai, OBI, Amgen, Pfizer, Macrogenics, Lilly; Speaker’s Bureau: Genomic Health; Hani Sbitany, MD – Consultant: LifeCell, Inc; David M. Schuster, MD - Grant/Research Support: Blue Earth Diagnostics Ltd, Nihon Medi-Physics Co Ltd (through Emory Office of Sponsored Projects); Consultant: American Imaging Management; Lawrence J. Solin, MD, FACR, FASTRO – Other: (not paid) Member, Advisory Board, GHI; Joseph Sparano, MD – AstraZeneca, Novartis, Celgene Corporation, Genentech/Roche, Lilly, Celldex Therapeutics; Catherine Van Poznak, MD – Grant/Research Support: Bayer; Other: Novartis (uncompensated) phase IV study steering committee.
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for CE purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, and management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER ®or any of the companies that provided commercial support for this activity.
For questions about this CME activity, please contact:
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Tel: (609) 378-3701
Fax: (609) 257-0705
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018